Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

However, a recent study from Sunnybrook Research Institute offers some hope. Researchers found that a type of diabetes ...

The findings were alarming. People who took at least one anticholinergic drug had a 47% higher risk of developing memory ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer ...